Examkin

Soru

Zorluk: ZorRheumatology and Immunology

A 45-year-old woman presents to the clinic with a 3-month history of symmetric pain, swelling, and morning stiffness in her metacarpophalangeal and proximal interphalangeal joints lasting up to 2 hours daily. Physical examination reveals active synovitis in multiple small joints of the hands. Laboratory evaluation is strongly positive for rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies. The patient is diagnosed with moderate-to-severe rheumatoid arthritis. Arrange the following steps in the most appropriate chronological sequence for the standard diagnostic workup and long-term pharmacologic management of this patient, according to current clinical guidelines.

  1. 1Perform baseline screening for latent tuberculosis, hepatitis B, and hepatitis C.
  2. 2Initiate first-line therapy with oral methotrexate and a bridging course of systemic glucocorticoids.
  3. 3Add a biologic DMARD (e.g., TNF-alpha inhibitor) if disease activity remains moderate to high after 3 to 6 months.
  4. 4Transition to a different biologic class (e.g., IL-6 inhibitor) or a targeted synthetic DMARD (e.g., JAK inhibitor).

Cevap

The correct sequence is: (1) Perform infectious disease screening, (2) Initiate methotrexate with bridging glucocorticoids, (3) Escalate to a TNF-alpha inhibitor if disease remains active, (4) Switch to an alternative biologic class if the initial biologic fails.
The management of rheumatoid arthritis follows a strict 'treat-to-target' algorithmic escalation. Because all major RA therapies are profoundly immunosuppressive, baseline screening for latent infections (TB, Hepatitis B/C) is a mandatory prerequisite to any disease-modifying therapy. Following screening, oral methotrexate is initiated as the first-line conventional synthetic DMARD, accompanied by a short course of glucocorticoids to bridge the delayed onset of methotrexate's efficacy. Patients are formally reassessed at 3 to 6 months; if they have not achieved remission or low disease activity, therapy is escalated by adding a biologic DMARD, most commonly a TNF-alpha inhibitor. Finally, if the initial biologic fails due to primary or secondary non-response, the subsequent step is switching to a medication with a different mechanism of action, such as an IL-6 inhibitor, an anti-CD20 monoclonal antibody (rituximab), or a targeted synthetic DMARD (JAK inhibitor).

Adım Adım Çözüm

1
Screen for latent infections (TB, Hepatitis B/C).
Ensures the patient does not have underlying latent infections.
Immunosuppressive therapies used in rheumatoid arthritis, particularly biologics, suppress critical immune pathways (like granuloma maintenance in TB), potentially causing fatal reactivation.
2
Start conventional synthetic DMARD therapy (Methotrexate) with bridging steroids.
Halts joint destruction long-term while rapidly controlling acute inflammation.
Methotrexate is the universal first-line agent for moderate-to-severe rheumatoid arthritis. Because it has a delayed onset of action, glucocorticoids are used temporarily to bridge the gap.
3
Assess response at 3-6 months and add a biologic DMARD (e.g., TNF-alpha inhibitor) if needed.
Escalates immunosuppression to achieve clinical remission or low disease activity.
Current guidelines recommend a 'treat-to-target' approach; if the target is not reached with conventional DMARDs alone, adding a biologic agent is the standard next step.
4
Switch to an alternative mechanism of action (e.g., IL-6 inhibitor, CD20 antibody, or JAK inhibitor).
Provides an alternative therapeutic pathway for disease control.
Used when a patient demonstrates primary non-response (lack of initial efficacy) or secondary loss of response (often due to anti-drug antibodies) to the first-line biologic.

Anahtar Kavram

Rheumatoid Arthritis Stepwise Pharmacologic Management
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru